Kovaks-19 (COVAX-19 ili SpikoGen ) je rekombinantna vakcina protiv kovida 19 zasnovana na proteinima koju je razvila biotehnološka kompanija Vaxine iz Južne Australije . U toku je kliničko ispitivanje vakcine u saradnji sa iranskom kompanijom CinnaGen .[2] [3] [4]
Klinička ispitivanja
uredi
^ Clinical Trials NCT04944368 Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)
^ „"Spikogen", A Joint Venture Between Vaxine And Cinnagen” . Vaxine. Arhivirano iz originala 11. 07. 2021. g. Pristupljeno 24. 01. 2022 .
^ a b „A phase III, Randomized, Two-armed, Double-blind, Placebo controlled trial to evaluate efficacy and safety of an adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen®) produced by CinnaGen Co. (Two doses of 25µg with dosing interval of 21 days)” . irct.ir . 2. 8. 2021. IRCT20150303021315N24. Pristupljeno 3. 8. 2021 .
^ Griffin P (23. 6. 2021). „What is COVAX-19? Australia's most advanced COVID vaccine candidate” . medicine.uq.edu.au (na jeziku: engleski). Pristupljeno 5. 8. 2021 .
^ Vaxine Pty Ltd (5. 5. 2021). „A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects” . Central Adelaide Local Health Network Incorporated.
^ „چرا واکسن اسپایکوژن؟ | واکسن کرونا اسپایکوژن | spikogen” (na jeziku: persijski). 26. 4. 2020. Arhivirano iz originala 09. 07. 2021. g. Pristupljeno 7. 9. 2021 .
^ „IRCT | A phase II, Randomized, Two-armed, Double-blind, Placebo controlled trial to evaluate efficacy and safety of an adjuvanted recombinant SARS-CoV-2 spike (S) protein subunit vaccine (SpikoGen®) produced by CinnaGen Co. (Two doses of 25µg with dosing interval of 21 days)” . en.irct.ir . Arhivirano iz originala 11. 07. 2021. g. Pristupljeno 7. 9. 2021 .
^ Cinnagen (14. 8. 2021). „A Phase II, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)” . Vaxine Pty Ltd.
^ Cinnagen (11. 8. 2021). „A Phase III, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)” . Vaxine Pty Ltd.
Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja) .